Patients who started taking a common supplement after their first skin cancer diagnosis cut their risk of developing another cancer by more than half, according to the largest study to date on the over-the-counter product.

The study , published recently in JAMA Dermatology , followed more than 33,000 veterans and found that patients who started the B3 derivative nicotinamide after their first skin cancer saw their risk drop by 54%. The findings suggest that timing is key: starting early offers the strongest protection, while waiting until multiple cancers have developed sharply reduces the benefit.

Led by Lee Wheless, M.D., Ph.D., an assistant professor of dermatology at Vanderbilt University Medical Center, the study provides guidance on when to use a supplement that roughly 75% of

See Full Page